公开(公告)号：US11541034B2

公开(公告)日：2023-01-03

申请号：US17554091

申请日：2021-12-17

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: A61K31/401 ,  A61K31/403 ,  C07D403/12 ,  A61K31/427 ,  A61P31/14

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20220142976A1

公开(公告)日：2022-05-12

申请号：US17554091

申请日：2021-12-17

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: A61K31/403 ,  A61K31/427 ,  A61P31/14 ,  C07D403/12

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20150175603A1

公开(公告)日：2015-06-25

申请号：US14405103

申请日：2013-06-03

Applicant: PFIZER INC.

Inventor： Amy Beth Dounay ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest

IPC: C07D471/14 ,  C07D471/06

CPC classification number: C07D471/14 ,  C07D471/04 ,  C07D471/06 ,  C07D498/04

Abstract: Compounds of Formula (I), wherein R1, R2, X1, Y1, Z1, and Z2 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

Abstract translation: 描述了其中R1，R2，X1，Y1，Z1和Z2如本文所定义的式（I）化合物及其药学上可接受的盐可用于治疗与精神分裂症，神经变性和其他精神病学，神经变性和 /或哺乳动物包括人类的神经障碍。

公开(公告)号：US20250099424A1

公开(公告)日：2025-03-27

申请号：US18917336

申请日：2024-10-16

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Qingyi Yang

IPC: A61K31/403 ,  A61K31/401 ,  A61K31/427 ,  A61P31/14 ,  C07D403/12

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20240197703A1

公开(公告)日：2024-06-20

申请号：US18144737

申请日：2023-05-08

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

CPC classification number: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11452711B2

公开(公告)日：2022-09-27

申请号：US17660270

申请日：2022-04-22

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Qingyi Yang

IPC: C07D403/12 ,  A61K31/403 ,  A61P31/14 ,  A61K31/427 ,  A61K31/401

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20220017548A1

公开(公告)日：2022-01-20

申请号：US17365213

申请日：2021-07-01

Applicant: Pfizer Inc.

Inventor： Robert Steven Kania ,  Padmavani Bezawada ,  Emma Louise Hawking ,  Rohit Jaini ,  Samir Kulkarni ,  Matthew Nathan O'Brien Laramy ,  Jonathan Richard Lillis ,  Suman Luthra ,  Dafydd Rhys Owen ,  Klimentina Dimitrova Pencheva ,  Martin Youngjin Pettersson ,  Anil Mahadeo Rane ,  Matthew Forrest Sammons ,  Bradley Paul Sullivan ,  Andrew John Thiel ,  Martyn David Ticehurst ,  Jamison Bryce Tuttle ,  Robert Louis Hoffman

IPC: C07F9/572 ,  A61P31/14

Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

公开(公告)号：US20140329820A1

公开(公告)日：2014-11-06

申请号：US14265458

申请日：2014-04-30

Applicant: Pfizer Inc.

Inventor： Thomas Allen Chappie ,  Christopher John Helal ,  Bethany Lyn Kormos ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest

IPC: C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07D471/04

CPC classification number: C07D519/00 ,  A61K31/4353 ,  A61K31/53 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.

Abstract translation: 本发明涉及如下式I所述的新一类三嗪衍生物，其中A，X，R 1，R 2，R 3和R 4如本文所定义，以及该化合物作为PDE10抑制剂的用途。

公开(公告)号：US20230120707A1

公开(公告)日：2023-04-20

申请号：US17906132

申请日：2021-03-31

Applicant: Pfizer Inc.

Inventor： Robert Steven Kania ,  Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle

IPC: C07D403/14 ,  A61K9/20 ,  A61K9/00

Abstract: The invention relates to compounds of formula I wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compound

公开(公告)号：US11351149B2

公开(公告)日：2022-06-07

申请号：US17395139

申请日：2021-08-05

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC: C07D403/12 ,  A61K31/403 ,  A61P31/14 ,  A61K31/427

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.